RANK-ligand inhibitor will have an additional year of data and market exclusivity in the EU. The European Commission approved Amgen’s Xgeva® (denosumab) monoclonal antibody for the prevention of ...
Approvals expand Amneal’s biosimilars portfolioCompany expects to commercialize six biosimilars across eight presentations by 2027BRIDGEWATER, ...
Amgen (Nasdaq: AMGN) today announced top-line results from a Phase 3 trial evaluating XGEVA(TM) (denosumab) versus placebo in 1,432 men with castrate-resistant prostate cancer. The trial, known as the ...
Amgen today announced the FDA plans to decide by April 26 on its application to expand the use of its bone treatment drug Xgeva to prevent or delay the spread of advanced prostate cancer. The drug is ...
LOS ANGELES, May 17 (Reuters) - A clinical trial of Amgen Inc's bone drug, Xgeva, found that it can significantly delay the time it takes for prostate cancer to cause bone pain -- a finding the ...
Sandoz has obtained the Food and Drug Administration’s clearance for Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), the only FDA-approved denosumab biosimilars, to treat all indications of ...
Novartis' (NYSE:NVS) unit Sandoz said on Monday that the U.S. Food and Drug Administration (FDA) accepted its biologics license application (BLA) for proposed biosimilar denosumab. The BLA includes ...
Amgen Inc (NASDAQ:AMGN) has reportedly sued Novartis AG's (NYSE:NVS) Generic arm Sandoz on proposed versions of its bone-strengthening drugs Prolia and Xgeva containing denosumab, infringing several ...
Yonhap News Agency on MSN
Celltrion launches biosimilar Stoboclo-Osenvelt in Europe
Celltrion Inc., a major South Korean biopharmaceutical company, said Monday it has launched its biosimilar drug Stoboclo-Osenvelt in major European markets, following the product's initial rollout in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback